Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2000

View Archived Issues

CV Therapeutics reports potential strategy for raising HDL cholesterol

Targeted Genetics forms new company based on cell therapy technology

Initial phase I results show good safety for Antrin photoangioplasty

SmithKline Beecham launches Paxil in Japan

Expert committee recommends continuation of Remune trial in Spain

Schering and MediGene begin HPV vaccine trial

Company Profile: Micromet

Baxter's new recombinant hemophilia therapy enters phase III

Oral bosentan effective as pulmonary hypertension therapy

AlphaGene identifies two genes associated with Alzheimer's disease

Irbesartan to be evaluated in clinical trial for new indication: heart failure

Update on proposed merger of Cambridge NeuroScience and CeNeS; Moraxen launched

Tripep presents first clinical results for novel anti-HIV agent with a new mode of action

CCI-779: a new rapamycin analogue targeting mTOR with a promising clinical profile

ACUTE II results presented at AHA sessions

D-Pharm and Nycomed Amersham begin imaging agent collaboration

Moenomycin degradation products and synthetic analogues studied at Advanced Medicine

PDE4 inhibitor YM-976 is first to show dissociation between antiinflammatory activity and emesis

Promising anxiolytic candidate under joint development by CoCensys and Wyeth-Ayerst

Use of new benzodiazepine derivatives for imaging thrombi

Novel ester of sPLA2 inhibitor has improved oral bioavailability

New melatonin derivatives and analogues for inducing sedation described in recent patent

Novel antiarrhythmic agents under study at Mochida

Sodium channel blockers and their use in the treatment of pain disclosed by Mochida

Uniroyal's potent new anti-HIV agents retain activity against strains carrying RT mutations

New oxytocin antagonists in development at Ferring for use in preterm labor, menstrual pain

Recent patent describes synthesis and use of indazole derivatives acting as 5-HT3/5-HT4 antagonists

NPY receptor ligands synthesized at Meiji Seika reduce food intake in animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...